New Cancer Dashboard on Gynaecological Cancers in Singapore
This Cancer Dashboard report examines the current landscape of gynaecological cancer care in Singapore, with a focus on cervical, endometrial, and ovarian cancer. It brings together publicly available national and international evidence to highlight key developments, outcomes and opportunities across prevention, early detection, diagnosis, treatment and supportive care, while comparing Singapore’s experience in an international context.
Overall, the dashboard shows a positive picture of gynaecological cancer care in Singapore, with room for further targeted actions to strengthen outcomes for patients and society. Gynaecological cancers accounted for 6,469 new cases, or 14% of all cancers diagnosed in women in Singapore, during 2019–2023. Singapore nevertheless compares favourably with several benchmark countries on mortality, and important progress has been made in cervical cancer prevention and control. In 2024, 88% of girls aged 15 had received two doses of the HPV vaccine, bringing Singapore close to the WHO target of 90% coverage by 2030 several years ahead of the deadline. Coverage increased rapidly following the introduction of school-based vaccination in 2019 and has remained close to 90% since 2022.
Cervical cancer incidence has halved since the 1990s and mortality has fallen substantially. At the same time, cervical screening participation was 45% in 2024 and remains uneven across population groups, indicating an opportunity to complement high vaccination coverage with stronger screening uptake. Progress has been less pronounced for ovarian and endometrial cancers, with ovarian cancer five-year survival remaining at 45% in 2019–2023 and endometrial cancer incidence increasing over time.
Singapore’s cancer care system combines relatively strong survival outcomes with broad financial protection and high-quality specialist services. Several recent policy changes also point towards a continued strengthening of patient support. These include expanded financing for medically necessary fertility preservation and the introduction of subsidised genetic testing for hereditary breast and ovarian cancer from December 2026, which is expected to improve access to hereditary cancer prevention and care.
The report identifies further opportunities to strengthen gynaecological cancer care, including assessing the potential benefits and cost-effectiveness of extending HPV vaccination to boys, improving information on cancer expenditure and societal costs, strengthening hereditary cancer and oncofertility pathways, and supporting access to high-value novel treatments.
For more information please contact Thomas Hofmarcher
Cancer Dashboard for Singapore – Gynaecological Cancers, IHE 2026, Lund, Sweden
Cite: Manzano A, Hofmarcher T. Cancer Dashboard for Singapore – Gynaecological Cancers, IHE 2026, Lund, Sweden
